The world's most neglected diseases.
作者信息
Yamey Gavin, Torreele Els
出版信息
BMJ. 2002 Jul 27;325(7357):176-7. doi: 10.1136/bmj.325.7357.176.
Abstract
摘要
相似文献
1
The world's most neglected diseases.世界上最被忽视的疾病。
BMJ. 2002 Jul 27;325(7357):176-7. doi: 10.1136/bmj.325.7357.176.
2
Eliminating neglected diseases: impact of published paper.消除被忽视疾病：已发表论文的影响
Health Aff (Millwood). 2007 Sep-Oct;26(5):1509. doi: 10.1377/hlthaff.26.5.1509.
3
Drug development for neglected diseases: a deficient market and a public-health policy failure.被忽视疾病的药物研发：市场缺陷与公共卫生政策失灵
Lancet. 2002 Jun 22;359(9324):2188-94. doi: 10.1016/S0140-6736(02)09096-7.
4
Staying ahead of the fourth horseman.
Nat Rev Microbiol. 2004 Sep;2(9):684. doi: 10.1038/nrmicro989.
5
The great medicines scandal.重大药品丑闻。
BMJ. 2006 Jun 10;332(7554):1345-6. doi: 10.1136/bmj.38868.651736.47. Epub 2006 Jun 1.
6
[Problems of updating antibacterial therapy].
Klin Med (Mosk). 1999;77(3):4-8.
7
Developing drugs for developing countries.为发展中国家研发药物。
Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.
8
Donated drugs boost protection against neglected tropical diseases.捐赠药物增强了对被忽视热带病的防护。
BMJ. 2013 Jan 16;346:f351. doi: 10.1136/bmj.f351.
9
Government action needed to step up research and development for world's most neglected diseases.需要政府采取行动，加强对全球最被忽视疾病的研发。
Expert Rev Anti Infect Ther. 2005 Dec;3(6):841-3. doi: 10.1586/14787210.3.6.841.
10
Prioritising neglected diseases related to poverty.优先考虑与贫困相关的被忽视疾病。
BMJ. 2005 Jul 2;331(7507):12. doi: 10.1136/bmj.331.7507.12.
引用本文的文献
1
Mutual Role of Patients and the Healthcare System in the Control of Cutaneous Leishmaniasis.患者与医疗保健系统在皮肤利什曼病控制中的相互作用
Transbound Emerg Dis. 2023 Aug 26;2023:7814940. doi: 10.1155/2023/7814940. eCollection 2023.
2
The developing role of NRF2 and HMOX1 in treatment response of cutaneous leishmaniasis.NRF2和HMOX1在皮肤利什曼病治疗反应中的发展作用。
Sci Rep. 2025 Apr 29;15(1):14988. doi: 10.1038/s41598-025-99456-0.
3
Molecular diagnosis and epidemiological aspects of cutaneous Leishmaniasis in Aleppo: Current status.阿勒颇皮肤利什曼病的分子诊断与流行病学情况：现状
Parasite Epidemiol Control. 2025 Jan 23;28:e00412. doi: 10.1016/j.parepi.2025.e00412. eCollection 2025 Feb.
4
Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.重新利用美国食品药品监督管理局（FDA）批准的药物治疗足菌肿：CYP51抑制剂的同源建模与计算筛选
Int J Mol Sci. 2025 Jan 1;26(1):315. doi: 10.3390/ijms26010315.
5
Understanding American tegumentary leishmaniasis in urban Montes Claros, Brazil: insights from clinical, immunological and therapeutic investigations.了解巴西蒙特斯克拉罗斯市城市地区的美洲皮肤利什曼病：来自临床、免疫学和治疗学调查的见解。
Parasitology. 2024 Sep;151(11):1260-1268. doi: 10.1017/S0031182024001057. Epub 2024 Nov 11.
6
Salivary antigens rPagSP02 and rPagSP06 are a reliable composite biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.唾液抗原 rPagSP02 和 rPagSP06 是评估斯里兰卡感染白蛉的可靠复合生物标志物。
Sci Rep. 2024 Oct 28;14(1):25863. doi: 10.1038/s41598-024-77666-2.
7
'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.“我们的项目，你的问题？” 世界卫生组织在南非的信使核糖核酸技术转让计划案例研究
PLOS Glob Public Health. 2024 Sep 23;4(9):e0003173. doi: 10.1371/journal.pgph.0003173. eCollection 2024.
8
rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.rPagSP02+rPagSP06重组唾液抗原是评估斯里兰卡银足白蛉暴露情况的可靠生物标志物。
Res Sq. 2024 Jul 19:rs.3.rs-4633976. doi: 10.21203/rs.3.rs-4633976/v1.
9
Targeting with Structural Analogs of Natural Products the Purine Salvage Pathway in by Computer-Aided Drug-Design Approaches.通过计算机辅助药物设计方法，以天然产物的结构类似物靶向[具体生物]中的嘌呤补救途径。 （你提供的原文中“in by”表述有误，推测可能是“in [具体生物] by”，这里按推测后的内容翻译，你可根据实际情况修改。）
Trop Med Infect Dis. 2024 Feb 3;9(2):41. doi: 10.3390/tropicalmed9020041.
10
Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan.伊朗伊斯兰共和国准备消除计划的皮肤利什曼病情况分析。
Front Public Health. 2023 Apr 28;11:1091709. doi: 10.3389/fpubh.2023.1091709. eCollection 2023.
本文引用的文献
1
Treatment of human African trypanosomiasis--present situation and needs for research and development.人类非洲锥虫病的治疗——现状以及研发需求
Lancet Infect Dis. 2002 Jul;2(7):437-40. doi: 10.1016/s1473-3099(02)00321-3.
2
Drug development for neglected diseases: a deficient market and a public-health policy failure.被忽视疾病的药物研发：市场缺陷与公共卫生政策失灵
Lancet. 2002 Jun 22;359(9324):2188-94. doi: 10.1016/S0140-6736(02)09096-7.
3
Public sector must develop drugs for neglected diseases.公共部门必须研发针对被忽视疾病的药物。
BMJ. 2002 Mar 23;324(7339):698. doi: 10.1136/bmj.324.7339.698/b.
4
The cost to global health of drug company profits.制药公司利润对全球健康造成的代价。
West J Med. 2001 May;174(5):302-3. doi: 10.1136/ewjm.174.5.302.
Zotero 插件